Abstract
About this talk
Mucormycosis is a rare, aggressive, angioinvasive fungal infection predominantly affecting immunocompromised individuals, particularly those with uncontrolled diabetes mellitus (DM). The incidence of COVID-19-associated mucormycosis increased substantially during the pandemic, particularly among patients treated with systemic corticosteroids. This case report highlights the severity of rhino-orbital mucormycosis following COVID-19 infection in a patient with uncontrolled DM.
A 58-year-old man with recently diagnosed DM presented with right-sided ptosis, proptosis, and progressively worsening painful visual loss over 10 days. He had recovered from COVID-19 infection 15 days earlier, during which he received systemic corticosteroids and antibiotics. Clinical examination revealed restricted extraocular movements, a fixed mid-dilated pupil, and no light perception in the right eye. Laboratory investigations demonstrated markedly elevated inflammatory markers and poor glycaemic control, with an HbA1c of 16.3%. Magnetic resonance imaging demonstrated extensive sinonasal disease with orbital involvement. Histopathological examination of nasal tissue confirmed mucormycosis. The patient received insulin therapy and intravenous liposomal amphotericin B, alongside extensive surgical debridement and endoscopic clearance. Although proptosis and painful eye movements improved following treatment, complete visual loss, ptosis, and restricted ocular movements persisted.
This case highlights the potentially devastating ocular and neurological complications of post-COVID mucormycosis in patients with uncontrolled DM. Early recognition, prompt antifungal treatment, aggressive surgical intervention, and optimisation of glycaemic control are essential to limit disease progression and improve clinical outcomes.
Speaker
About the speaker

